DK3280257T3 - Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr - Google Patents

Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr Download PDF

Info

Publication number: DK3280257T3
Authority: DK; Denmark
Prior art keywords: humanized; cell; immune response; human animals; mediated immune
Prior art date: 2015-04-06

Application number

DK16766106.5T

Other languages

English (en)

Inventor

Lynn Macdonald

Andrew J Murphy

Christos Kyratsous

Cagan Gurer

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-04-06

Filing date

2016-04-06

Publication date

2023-09-04

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56926255&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3280257(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2016-04-06 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2023-09-04 Application granted granted Critical

2023-09-04 Publication of DK3280257T3 publication Critical patent/DK3280257T3/da

Classifications

- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70517—CD8
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Environmental Sciences (AREA)
Cell Biology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Veterinary Medicine (AREA)
Biodiversity & Conservation Biology (AREA)
Animal Husbandry (AREA)
Animal Behavior & Ethology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Plant Pathology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DK16766106.5T 2015-04-06 2016-04-06 Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr DK3280257T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201562143687P	2015-04-06	2015-04-06
US201562158804P	2015-05-08	2015-05-08
US201562186935P	2015-06-30	2015-06-30
PCT/US2016/026260 WO2016164492A2 (en)	2015-04-06	2016-04-06	Humanized t cell mediated immune responses in non-human animals

Publications (1)

Publication Number	Publication Date
DK3280257T3 true DK3280257T3 (da)	2023-09-04

Family

ID=56926255

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK16766106.5T DK3280257T3 (da)	2015-04-06	2016-04-06	Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr

Country Status (24)

Country	Link
US (2)	US11259510B2 (da)
EP (2)	EP4248744A3 (da)
JP (5)	JP6796597B2 (da)
KR (2)	KR20240132525A (da)
CN (2)	CN113349159B (da)
AU (3)	AU2016246698B2 (da)
CA (2)	CA3223798A1 (da)
DK (1)	DK3280257T3 (da)
ES (1)	ES2954865T3 (da)
FI (1)	FI3280257T3 (da)
HR (1)	HRP20231039T1 (da)
HU (1)	HUE064168T2 (da)
IL (4)	IL297097B2 (da)
LT (1)	LT3280257T (da)
MX (2)	MX2017012829A (da)
NZ (1)	NZ736031A (da)
PL (1)	PL3280257T3 (da)
PT (1)	PT3280257T (da)
RS (1)	RS64540B1 (da)
RU (1)	RU2732628C2 (da)
SG (2)	SG10201909320UA (da)
SI (1)	SI3280257T1 (da)
SM (1)	SMT202300408T1 (da)
WO (1)	WO2016164492A2 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9591835B2 (en)	2011-10-28	2017-03-14	Regeneron Pharmaceuticals, Inc.	Genetically modified major histocompatibility complex animals
LT3590332T (lt)	2011-10-28	2022-08-10	Regeneron Pharmaceuticals, Inc.	Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules
IN2014CN03890A (da)	2011-10-28	2015-10-16	Regeneron Pharma
LT3262932T (lt)	2011-10-28	2019-08-26	Regeneron Pharmaceuticals, Inc.	Pelės su genetiškai modifikuotu pagrindiniu histosuderinamumo kompleksu
SMT201900429T1 (it)	2013-02-20	2019-09-09	Regeneron Pharma	Topi esprimenti co-recettori umanizzati linfociti t
EP2958937B1 (en)	2013-02-22	2018-08-15	Regeneron Pharmaceuticals, Inc.	Mice expressing humanized major histocompatibility complex
US20150342163A1 (en)	2013-02-22	2015-12-03	Regeneron Pharmaceuticals, Inc.	Genetically modified major histocompatibility complex mice
LT3376857T (lt)	2015-11-20	2021-06-25	Regeneron Pharmaceuticals, Inc.	Gyvūnai, ne žmonės, turintys humanizuotą limfocitų aktyvavimo geną
CN109068621B (zh)	2016-02-29	2021-07-20	再生元制药公司	具有人源化的tmprss基因的啮齿类动物
EP3462853B1 (en)	2016-06-03	2023-03-01	Regeneron Pharmaceuticals, Inc.	Rodents expressing exogenous terminal deoxynucleotidyltransferase
WO2019067875A1 (en)	2017-09-29	2019-04-04	Regeneron Pharmaceuticals, Inc.	NON-HUMAN ANIMALS COMPRISING A HUMANIZED TTR LOCUS AND METHODS OF USE
IL273828B2 (en) *	2017-10-19	2024-06-01	Cellectis Sa	Targeted gene integration of nk inhibitors genes for improved immune cells therapy
AU2018375796B2 (en)	2017-11-30	2024-11-21	Regeneron Pharmaceuticals, Inc.	Non-human animals comprising a humanized TRKB locus
US11747340B2 (en)	2018-03-24	2023-09-05	Regeneron Pharmaceuticals, Inc.	Systems and methods for identifying HLA-associated tumor peptides
AU2019242586B2 (en)	2018-03-26	2025-09-11	Regeneron Pharmaceuticals, Inc.	Humanized rodents for testing therapeutic agents
PL3823443T3 (pl)	2018-07-16	2024-09-23	Regeneron Pharmaceuticals, Inc.	Modele gryzoni z chorobą ditra i ich zastosowania
JP7569313B2 (ja)	2018-10-23	2024-10-17	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	Ｎｙ－ｅｓｏ－１ｔ細胞受容体およびそれらの使用の方法
EP3873540A4 (en)	2018-10-31	2022-07-27	Mayo Foundation for Medical Education and Research	METHODS AND MATERIALS FOR THE TREATMENT OF CANCER
WO2020092839A1 (en) *	2018-10-31	2020-05-07	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
IL286905B2 (en)	2019-04-04	2024-06-01	Regeneron Pharma	Non-human animals containing the human coagulation factor 12 locus
AU2020264484A1 (en)	2019-05-01	2021-11-04	Adoc Ssf, Llc	Compositions and methods for the treatment of cancer using a CDB engineered T cell therapy
WO2020247452A1 (en)	2019-06-04	2020-12-10	Regeneron Pharmaceuticals, Inc.	Non-human animals comprising a humanized ttr locus with a beta-slip mutation and methods of use
SG11202111256XA (en)	2019-06-07	2021-11-29	Regeneron Pharma	Non-human animals comprising a humanized albumin locus
EP4041868A1 (en) *	2019-10-03	2022-08-17	Regeneron Pharmaceuticals, Inc.	High-throughput method to screen cognate t cell and epitope reactivities in primary human cells
IL294988A (en)	2020-01-24	2022-09-01	Regeneron Pharma	Antigen preferentially expressed in melanoma t-cell receptors (prame) and methods of using them
AU2022249328A1 (en) *	2021-03-31	2023-09-21	Regeneron Pharmaceuticals, Inc.	Genetically modified mice comprising humanized cellular immune system components with improved diversity of tcrβ repertoire
WO2023092119A2 (en)	2021-11-22	2023-05-25	Ludwig Institute For Cancer Research Ltd	Methods for predicting responsiveness to a cancer therapy
CN113999873B (zh) *	2021-12-31	2022-05-20	北京市疾病预防控制中心	一种基因修饰的非人动物的构建方法及其应用
CN115074368B (zh) *	2022-06-09	2023-08-08	澳门科技大学	一种耐药型类风湿性关节炎动物模型的构建及其应用
KR20250077529A (ko) *	2022-09-22	2025-05-30	리제너론 파아마슈티컬스, 인크.	인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스
IL320128A (en)	2022-10-31	2025-06-01	Regeneron Pharma	Methods for treating cancer using a combination of adoptive cell therapy and a targeted immunocytokine
WO2024112806A1 (en) *	2022-11-21	2024-05-30	Moonwalk Biosciences, Inc.	Generation and use of epigenetic maps for drug discovery
WO2024211478A1 (en)	2023-04-07	2024-10-10	Regeneron Pharmaceuticals, Inc.	Methods of treating cancer with a lymphotoxin beta receptor agonist
WO2024243511A1 (en)	2023-05-25	2024-11-28	Regeneron Pharmaceuticals, Inc.	T cell receptors that bind presented hpv16-, mart1-, cmv-, ebv-, or influenza- peptides
TW202520975A (zh) *	2023-08-09	2025-06-01	英商劍橋企業有限公司	基因改造之囓齒動物及囓齒動物細胞以及其等用途
WO2025064761A1 (en)	2023-09-22	2025-03-27	Regeneron Pharmaceuticals, Inc.	Kras10-18 g12d off-target peptides and uses thereof
WO2025064738A1 (en)	2023-09-22	2025-03-27	Regeneron Pharmaceuticals, Inc.	Dntt 250-258 off-target peptides and uses thereof

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5958678A (en)	1986-08-21	1999-09-28	The Trustees Of Columbia University In The City Of New York	DNA encoding the T cell surface protein T4 and use of fragments of T4 in the treatment of AIDS
US5175384A (en)	1988-12-05	1992-12-29	Genpharm International	Transgenic mice depleted in mature t-cells and methods for making transgenic mice
AU633958B2 (en)	1989-07-25	1993-02-11	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
US5574205A (en)	1989-07-25	1996-11-12	Cell Genesys	Homologous recombination for universal donor cells and chimeric mammalian hosts
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
GB9100481D0 (en)	1991-01-10	1991-02-20	Inst Nat Sante Rech Med	Genetically engineered mice
WO1993005817A1 (en)	1991-09-19	1993-04-01	President And Fellows Of Harvard College	Transgenic mhc class i and class ii antigen-deficient mammals
EP0663952A4 (en)	1992-09-11	1997-06-11	Univ California	Transgenic non-human animals having targeted lymphocyte transduction genes.
US5523226A (en) *	1993-05-14	1996-06-04	Biotechnology Research And Development Corp.	Transgenic swine compositions and methods
GB9315303D0 (en)	1993-07-23	1993-09-08	Zeneca Ltd	Polypeptide
US5965787A (en)	1995-08-31	1999-10-12	Mayo Foundation For Medical Education And Research	HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis
US6002066A (en)	1996-01-16	1999-12-14	Ortho Pharmaceutical Corp.	H2-M modified transgenic mice
EP0910409A4 (en)	1996-03-05	2003-03-19	Scripps Research Inst	RECOMBINANT GENE CONSTRUCTS ENCODING T-CELL RECEPTORS SPECIFIC TO HUMAN-RESTRICTED TUMORANTANTIGENS
EP2305027B1 (en)	1996-12-03	2014-07-02	Amgen Fremont Inc.	Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
AU741130B2 (en)	1997-09-16	2001-11-22	Oregon Health Sciences University	Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US6372955B1 (en)	1998-02-17	2002-04-16	Ortho Mcneil Pharmaceutical, Inc.	Methods for Producing B cells and antibodies from H2-O modified transgenic mice
WO2001027291A1 (en)	1999-10-12	2001-04-19	Institut Pasteur	Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice
US7462486B2 (en)	2000-05-12	2008-12-09	Oregon Health & Science University	Methods of selecting T cell receptor V peptides for therapeutic use
US20030124524A1 (en)	2000-06-23	2003-07-03	Kenneth Kornman	Screening assays for identifying modulators of the inflammatory or immune response
US6911204B2 (en) *	2000-08-11	2005-06-28	Favrille, Inc.	Method and composition for altering a B cell mediated pathology
US7105348B2 (en)	2000-10-31	2006-09-12	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
US6586251B2 (en)	2000-10-31	2003-07-01	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
JPWO2002047474A1 (ja)	2000-12-13	2004-04-15	住友製薬株式会社	Ｈｌａ−ａ２４発現トランスジェニック動物及びその利用
US20030093818A1 (en)	2000-12-19	2003-05-15	Belmont Heather J.	Transgenic animals comprising a humanized immune system
FR2827302B1 (fr)	2001-07-13	2003-10-10	Genoway	Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
CA2457652C (en) *	2001-08-31	2012-08-07	Avidex Limited	Soluble t cell receptor
US20050177884A1 (en)	2001-11-15	2005-08-11	Kirin Beer Kabushiki Kaisha	Chimeric nonhuman animal
WO2003068819A1 (en)	2001-12-22	2003-08-21	4-Antibody Ag	Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
US8895020B2 (en)	2002-04-19	2014-11-25	Washington University	Single chain trimers and uses therefor
DE10244457A1 (de)	2002-09-24	2004-04-01	Johannes-Gutenberg-Universität Mainz	Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
EP1549748B1 (en)	2002-10-09	2014-10-01	Immunocore Ltd.	Single chain recombinant t cell receptors
US20040072262A1 (en)	2002-10-11	2004-04-15	Montero-Julian Felix A.	Methods and systems for detecting MHC class I binding peptides
US20060156419A1 (en)	2002-10-30	2006-07-13	The Wistar Institute Of Anatomy And Biology	Mouse model for autoimmune disorders
US7663017B2 (en)	2003-07-30	2010-02-16	Institut Pasteur	Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications
DE10347710B4 (de)	2003-10-14	2006-03-30	Johannes-Gutenberg-Universität Mainz	Rekombinante Impfstoffe und deren Verwendung
JP4857450B2 (ja)	2004-03-09	2012-01-18	財団法人名古屋産業科学研究所	ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物
PL1802193T3 (pl)	2004-10-19	2014-09-30	Regeneron Pharma	Sposób wytwarzania myszy homozygotycznej pod względem modyfikacji genetycznej
AU2007248019B2 (en)	2006-05-03	2012-10-11	Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Chimeric T cell receptors and related materials and methods of use
EP1878342A1 (en)	2006-07-13	2008-01-16	Institut Pasteur	Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses
EP1878798A1 (en)	2006-07-13	2008-01-16	Institut Pasteur	Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies
CN101534859B (zh) *	2006-09-08	2017-06-09	米迪缪尼有限公司	人源化抗cd19抗体及其在治疗癌症、移植病和自身免疫病中的应用
WO2008051854A2 (en)	2006-10-20	2008-05-02	Trustees Of Boston University	A tunable genetic switch for regulating gene expression
NO347649B1 (no)	2006-12-14	2024-02-12	Regeneron Pharma	Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP2262898B1 (en)	2008-03-07	2018-01-24	Regeneron Pharmaceuticals, Inc.	Es cell-derived mice from diploid host embryo injection
US20090328240A1 (en)	2008-06-24	2009-12-31	Sing George L	Genetically modified mice as predictors of immune response
WO2010107400A1 (en)	2009-03-20	2010-09-23	Agency For Science, Technology And Research	Genetically modified animal and method of obtaining the same
EP2517556B2 (en)	2009-07-08	2023-03-22	Kymab Limited	Site-Specific Recombination Method, Rodents & Rodent Cells capable of Expressing Chimaeric Antibodies or Chains
RU2425880C2 (ru) *	2009-07-30	2011-08-10	Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН	Способ получения трансгенных мышей
GB0917090D0 (en)	2009-09-29	2009-11-11	Ucl Biomedica Plc	T-cell receptor
CA2777053A1 (en)	2009-10-06	2011-04-14	The Board Of Trustees Of The University Of Illinois	Human single-chain t cell receptors
US8956828B2 (en)	2009-11-10	2015-02-17	Sangamo Biosciences, Inc.	Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
CA2805479A1 (en)	2010-07-15	2012-01-19	Technion Research & Development Foundation Ltd.	Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides
WO2012039779A1 (en)	2010-09-24	2012-03-29	The United States Of America As Represented By The Secretary Of The Navy	Humanized transgenic mouse model
CN103348012B (zh)	2010-11-27	2016-06-08	朱坚	一种人源化的转基因动物
US9591835B2 (en)	2011-10-28	2017-03-14	Regeneron Pharmaceuticals, Inc.	Genetically modified major histocompatibility complex animals
US9043996B2 (en)	2011-10-28	2015-06-02	Regeneron Pharmaceuticals, Inc.	Genetically modified major histocompatibility complex animals
LT3262932T (lt)	2011-10-28	2019-08-26	Regeneron Pharmaceuticals, Inc.	Pelės su genetiškai modifikuotu pagrindiniu histosuderinamumo kompleksu
IN2014CN03890A (da)	2011-10-28	2015-10-16	Regeneron Pharma
WO2013063556A1 (en)	2011-10-28	2013-05-02	Regeneron Pharmaceuticals, Inc.	Humanized il-6 and il-6 receptor
LT3590332T (lt)	2011-10-28	2022-08-10	Regeneron Pharmaceuticals, Inc.	Genetiškai modifikuotos pelės, ekspresuojančios chimerines pagrindinio audinių dermės komplekso (mhc) ii molekules
ES2748662T3 (es)	2012-11-05	2020-03-17	Institute For Res In Biomedicine Irb	Roedores inmunodeficientes modificados genéticamente y métodos de uso de los mismos
SMT201900429T1 (it)	2013-02-20	2019-09-09	Regeneron Pharma	Topi esprimenti co-recettori umanizzati linfociti t
EP2958937B1 (en)	2013-02-22	2018-08-15	Regeneron Pharmaceuticals, Inc.	Mice expressing humanized major histocompatibility complex
US20150342163A1 (en)	2013-02-22	2015-12-03	Regeneron Pharmaceuticals, Inc.	Genetically modified major histocompatibility complex mice
WO2014164640A1 (en) *	2013-03-11	2014-10-09	Regeneron Pharmaceuticals, Inc.	Transgenic mice expressing chimeric major histocompatibility complex (mhc) class i molecules
JP6456350B2 (ja)	2013-03-11	2019-01-23	リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎＰｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ．	キメラ主要組織適合複合体（ｍｈｃ）クラスｉｉ分子を発現する遺伝子導入マウス

2016
- 2016-04-06 DK DK16766106.5T patent/DK3280257T3/da active
- 2016-04-06 ES ES16766106T patent/ES2954865T3/es active Active
- 2016-04-06 LT LTEPPCT/US2016/026260T patent/LT3280257T/lt unknown
- 2016-04-06 PL PL16766106.5T patent/PL3280257T3/pl unknown
- 2016-04-06 KR KR1020247028283A patent/KR20240132525A/ko active Pending
- 2016-04-06 SI SI201631742T patent/SI3280257T1/sl unknown
- 2016-04-06 CN CN202110308348.7A patent/CN113349159B/zh active Active
- 2016-04-06 CN CN201680030625.XA patent/CN107666828B/zh active Active
- 2016-04-06 EP EP23175865.7A patent/EP4248744A3/en active Pending
- 2016-04-06 HR HRP20231039TT patent/HRP20231039T1/hr unknown
- 2016-04-06 FI FIEP16766106.5T patent/FI3280257T3/fi active
- 2016-04-06 JP JP2017552483A patent/JP6796597B2/ja active Active
- 2016-04-06 WO PCT/US2016/026260 patent/WO2016164492A2/en not_active Ceased
- 2016-04-06 RU RU2017137786A patent/RU2732628C2/ru active
- 2016-04-06 MX MX2017012829A patent/MX2017012829A/es unknown
- 2016-04-06 IL IL297097A patent/IL297097B2/en unknown
- 2016-04-06 KR KR1020177032048A patent/KR102699643B1/ko active Active
- 2016-04-06 IL IL318990A patent/IL318990A/en unknown
- 2016-04-06 SM SM20230408T patent/SMT202300408T1/it unknown
- 2016-04-06 CA CA3223798A patent/CA3223798A1/en active Pending
- 2016-04-06 HU HUE16766106A patent/HUE064168T2/hu unknown
- 2016-04-06 NZ NZ736031A patent/NZ736031A/en unknown
- 2016-04-06 EP EP16766106.5A patent/EP3280257B1/en active Active
- 2016-04-06 AU AU2016246698A patent/AU2016246698B2/en active Active
- 2016-04-06 IL IL284809A patent/IL284809B2/en unknown
- 2016-04-06 SG SG10201909320U patent/SG10201909320UA/en unknown
- 2016-04-06 US US15/564,723 patent/US11259510B2/en active Active
- 2016-04-06 RS RS20230771A patent/RS64540B1/sr unknown
- 2016-04-06 CA CA2980771A patent/CA2980771C/en active Active
- 2016-04-06 SG SG11201707691WA patent/SG11201707691WA/en unknown
- 2016-04-06 PT PT167661065T patent/PT3280257T/pt unknown
2017
- 2017-09-28 IL IL254775A patent/IL254775A0/en unknown
- 2017-10-05 MX MX2023002653A patent/MX2023002653A/es unknown
2020
- 2020-05-14 JP JP2020085069A patent/JP2020115896A/ja not_active Withdrawn
2022
- 2022-01-13 US US17/575,450 patent/US20220174921A1/en active Pending
- 2022-08-01 JP JP2022122754A patent/JP2022140609A/ja not_active Withdrawn
- 2022-08-26 AU AU2022221563A patent/AU2022221563B2/en active Active
2023
- 2023-10-18 JP JP2023179453A patent/JP7763820B2/ja active Active
2024
- 2024-07-17 JP JP2024114035A patent/JP7555515B1/ja active Active
2025
- 2025-05-06 AU AU2025203245A patent/AU2025203245A1/en active Pending

Also Published As

Publication number	Publication date
SG11201707691WA (en)	2017-10-30
HRP20231039T1 (hr)	2023-12-22
CN107666828A (zh)	2018-02-06
RU2732628C2 (ru)	2020-09-21
BR112017021250A2 (pt)	2018-06-26
IL284809B2 (en)	2023-03-01
JP2022140609A (ja)	2022-09-26
MX2017012829A (es)	2018-02-23
EP3280257A2 (en)	2018-02-14
AU2022221563B2 (en)	2025-05-29
IL297097A (en)	2022-12-01
AU2022221563A1 (en)	2022-10-13
SMT202300408T1 (it)	2024-01-10
CN107666828B (zh)	2021-04-09
US20220174921A1 (en)	2022-06-09
AU2016246698B2 (en)	2022-06-02
IL297097B1 (en)	2025-03-01
AU2025203245A1 (en)	2025-05-29
EP4248744A2 (en)	2023-09-27
JP2018513683A (ja)	2018-05-31
EP3280257B1 (en)	2023-06-07
PL3280257T3 (pl)	2023-10-23
IL284809B (en)	2022-11-01
JP6796597B2 (ja)	2020-12-09
KR20240132525A (ko)	2024-09-03
CA3223798A1 (en)	2016-10-13
EP4248744A3 (en)	2023-12-27
JP2020115896A (ja)	2020-08-06
JP7763820B2 (ja)	2025-11-04
CN113349159A (zh)	2021-09-07
JP7555515B1 (ja)	2024-09-24
PT3280257T (pt)	2023-09-12
AU2016246698A1 (en)	2017-10-26
IL284809A (en)	2021-08-31
US11259510B2 (en)	2022-03-01
CN113349159B (zh)	2022-11-11
KR20170133498A (ko)	2017-12-05
HUE064168T2 (hu)	2024-02-28
RU2017137786A3 (da)	2019-09-30
CA2980771C (en)	2024-02-06
RU2017137786A (ru)	2019-05-08
MX2023002653A (es)	2023-03-28
HK1250884A1 (en)	2019-01-18
US20180139940A1 (en)	2018-05-24
RS64540B1 (sr)	2023-09-29
SI3280257T1 (sl)	2023-10-30
WO2016164492A3 (en)	2016-12-15
CA2980771A1 (en)	2016-10-13
NZ736031A (en)	2022-07-29
KR102699643B1 (ko)	2024-08-28
IL318990A (en)	2025-04-01
ES2954865T3 (es)	2023-11-27
JP2023174872A (ja)	2023-12-08
JP2024133736A (ja)	2024-10-02
WO2016164492A2 (en)	2016-10-13
SG10201909320UA (en)	2019-11-28
IL297097B2 (en)	2025-07-01
LT3280257T (lt)	2023-09-25
IL254775A0 (en)	2017-12-31
FI3280257T3 (fi)	2023-09-07

Publication	Publication Date	Title
DK3280257T3 (da)	2023-09-04	Humaniseret T-celle-formidlet immunrespons i ikke-humane dyr
IL288264A (en)	2022-01-01	Genetically modified non-human animals expressing human epo
IL258437B (en)	2021-05-31	Growing systems and methods
EP3636073C0 (en)	2023-11-15	HUMANIZED C5 AND C3 ANIMALS
UY4533S (es)	2017-05-31	Tostadora
DK3689140T3 (da)	2022-08-01	Ikke-humane dyr, der eksprimerer humaniseret cd3-kompleks
DK3507373T3 (da)	2023-10-30	Genetisk modificeret ikke-menneskeligt dyr med human eller kimær pd-l1
DK3436773T3 (da)	2021-07-12	Legetøjsscanner
DK3129400T3 (da)	2020-06-08	Ikke-humane dyr med humaniserede Fc-gamma-receptorer
HUE046181T2 (hu)	2020-02-28	Javított ellenanyagok IL-6 ellen
EP4230711C0 (en)	2025-04-23	BRIQUETTES
DK3458080T3 (da)	2024-10-14	Polypeptidmodulerende siglec-afhængige immunreaktioner
DK3228312T3 (da)	2020-04-20	Immunregulator
DE112017000994A5 (de)	2018-12-13	Laserbarren mit gräben
DK3571208T3 (da)	2021-05-10	Immunproteasominhibitorer
DK3288431T3 (da)	2019-09-23	Engangsgrill
EP3442385C0 (de)	2024-08-14	Grill
EP3351145A4 (en)	2019-02-06	SOFA BED
EP3434547A4 (en)	2019-04-24	FALL PROTECTION DEVICE
EP3434548A4 (en)	2019-04-24	FALL PROTECTION DEVICE
NO3050465T3 (no)	2018-08-04	Seating
EP3559913A4 (en)	2020-01-08	INTERACTIVE CINEMAGRAMS
FR3036273B3 (fr)	2017-07-21	Grill cinq en un
DE112016001950A5 (de)	2018-02-01	Sitzgruppe
UY4596S (es)	2018-04-30	Tostadora